Observational studyBreast cancer research : BCR2026

Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive metastatic breast cancer.

Sherry Shen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.